Article
Surgery
Mathieu D'Hondt, Zoe Pironet, Isabelle Parmentier, Celine De Meyere, Marc Besselink, Hans Pottel, Franky Vansteenkiste, Chris Verslype
Summary: This study compared the short- and long-term outcomes of laparoscopic liver resections for bilobar colorectal liver metastases (CRLM) to single resections for CRLM. The results showed that in experienced hands, performing laparoscopic liver resections for bilobar CRLM can be done safely with similar oncologic outcomes as those who underwent single resections for CRLM.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2022)
Article
Surgery
Yuzo Umeda, Takeshi Nagasaka, Kosei Takagi, Ryuichi Yoshida, Kazuhiro Yoshida, Tomokazu Fuji, Tatsuo Matsuda, Kazuya Yasui, Kenjiro Kumano, Hiroki Sato, Takahito Yagi, Toshiyoshi Fujiwara
Summary: VESPAH surgery allows for precise surgical navigation through hepatic vessel skeletonization, leading to earlier recovery of remnant liver function, reduced incidence of post-hepatectomy liver failure, and higher rates of adjuvant chemotherapy initiation and repeat hepatectomies for intrahepatic recurrence.
LANGENBECKS ARCHIVES OF SURGERY
(2022)
Review
Biochemistry & Molecular Biology
Daniel-Clement Osei-Bordom, Sivesh Kamarajah, Niki Christou
Summary: In the clinical management of liver metastasis of colorectal cancer, surgeons and oncologists categorize the metastasis into resectable and non-resectable groups to initiate tailored therapeutics. The combination of targeted therapies and biotherapies around these two entities is being actively explored to determine the ideal conditions for their application to improve patient survival and quality of life.
Article
Surgery
Bobby V. M. Dasari, Dimitri Raptis, Nicholas Syn, Alejandro Serrablo, Jose Manuel Ramia, Andrea Laurenzi, Christian Sturesson, Timothy M. Pawlik, Ajith K. Siriwardena, Mickael Lesurtel, Scientific Committee of E-AHPBA
Summary: A retrospective international multicentre study was conducted to assess the clinical and pathological determinants of overall survival and recurrence-free survival among patients undergoing surgical clearance of bilobar liver metastases from colorectal cancer. The study included 1236 patients from 70 centres, majority with synchronous liver metastases. Overall survival rates at 1, 2, 3, and 5 years were 86.4%, 67.5%, 52.6%, and 33.8% respectively, with recurrence-free survival rates of 48.7%, 26.6%, 19.2%, and 10.5%. Adjuvant chemotherapy in margin-positive resections showed a survival advantage. The study developed a prognostic nomogram for overall survival with high accuracy.
Review
Oncology
Alexandra Nassar, Stylianos Tzedakis, Alix Dhote, Marie Strigalev, Romain Coriat, Mehdi Karoui, Anthony Dohan, Martin Gaillard, Ugo Marchese, David Fuks
Summary: This literature review aimed to assess the feasibility of laparoscopic liver resection for multiple colorectal liver metastases. The minimally invasive approach for liver cancer has become a new standard of oncological care, and laparoscopic liver resection is a significant indication for multiple colorectal liver metastases. The purpose of this paper was to highlight the novelty and updates in the field of multiple minimally invasive liver resections and discuss the feasibility and outcomes of laparoscopic concomitant multiple liver resections for colorectal liver metastases.
Article
Oncology
Myrtle F. Krul, Sarah L. Gerritsen, Frederique L. Vissers, Elisabeth G. Klompenhouwer, Theo J. M. Ruers, Koert F. D. Kuhlmann, Niels F. M. Kok
Summary: Intraoperative RFA and MWA were equally effective for treatment of small CRLM.
Article
Surgery
G. E. Wensink, Karen Bolhuis, Marloes A. G. Elferink, Remond J. A. Fijneman, Onno Kranenburg, Inne H. M. Borel Rinkes, Miriam Koopman, Rutger-Jan Swijnenburg, Geraldine R. Vink, Jeroen Hagendoorn, Cornelis J. A. Punt, Jeanine M. L. Roodhart, Sjoerd G. Elias
Summary: A prediction model for early extrahepatic recurrence (EHR) after local treatment of colorectal liver metastases (CRLMs) has been developed, which can predict 6-month EHR using routine clinical information and assist in clinical decision-making.
BRITISH JOURNAL OF SURGERY
(2023)
Article
Oncology
Moritz Drefs, Markus B. Schoenberg, Tobias S. Schiergens, Markus Albertsmeier, Joachim Andrassy, Martin K. Angele, Christoph B. Westphalen, Max Seidensticker, Jens Werner, Markus O. Guba
Summary: In the treatment of colorectal liver metastases, completing hepatic clearance is crucial for long-term survival. Factors such as patient age, comorbidities, complications, and prolonged ICU stay may contribute to incomplete clearance of CRC-LM.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Astrid Bauschke, Annelore Altendorf-Hofmann, Merten Homman, Thomas Manger, Joerg Pertschy, Herry Helfritzsch, Hubert Goebel, Utz Settmacher
Summary: The study retrospectively analyzed data from 637 patients between 1995 and 2018, finding that different factors affect the survival rates of patients with different tumor entities, and the Adam score can identify risk factors for most but not all tumor entities.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Review
Cell Biology
Diamantis I. Tsilimigras, Ioannis Ntanasis-Stathopoulos, Timothy M. Pawlik
Summary: The liver is a common site for metastasis in colorectal cancer patients due to the direct connection between the colon and rectum and the liver through the portal vein circulation. The liver tumor microenvironment consists of different cell types that modulate antigen recognition and immune system activation. Primary tumors from other sites create a pre-metastatic niche in the liver before the seeding of cancer cells. There are four key phases in the development of liver metastases: microvascular infiltration, extravascular pre-angiogenesis, angiogenesis, and tumor growth.
Article
Surgery
Jenna N. Whitrock, Stephen J. Hartman, Shimul A. Shah
Summary: In patients with unresectable liver metastases from colorectal cancer, chemotherapy alone is associated with significant mortality. Liver transplant is emerging as a promising treatment alternative for appropriately selected patients. Several key clinical trials, including SECA-I and SECA-II, have demonstrated promising survival outcomes, and further trials are ongoing to evaluate the safety of this approach.
Article
Surgery
Fasih Ali Ahmed, Mohamedraed Elshami, Jonathan J. Hue, Hanna Kakish, Lauren M. Drapalik, Lee M. Ocuin, Jeffrey M. Hardacre, John B. Ammori, Emily Steinhagen, Luke D. Rothermel, Richard S. Hoehn
Summary: This study finds that nonmedical patient factors such as race, socioeconomic status, and geography are associated with treatment and survival for isolated colorectal liver metastases. Disparities persist after adjusting for surgical resection and treatment facility. These barriers must be addressed to improve care for vulnerable cancer patients.
Review
Biochemistry & Molecular Biology
Carolin Czauderna, Kim Luley, Nikolas von Bubnoff, Jens U. Marquardt
Summary: Liver metastases are the most common site of metastasis in colorectal cancer. Current treatment approaches involve systemic therapies and surgical/interventional strategies, with the use of predictive and prognostic biomarkers leading to improved survival rates. Treatment selection based on patient status, tumor characteristics, and molecular/genetic status is recommended for better outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Drew Maclean, Maria Tsakok, Fergus Gleeson, David J. Breen, Robert Goldin, John Primrose, Adrian Harris, James Franklin
Summary: Colorectal liver metastases exhibit heterogenous histopathological and immunohistochemical phenotypes, impacting treatment responses and outcomes. Advanced imaging techniques like multiparametric MRI and functional imaging have the potential to provide clinically-actionable phenotypic characterisation. Advanced analysis techniques such as radiomics and machine learning play a growing role in linking imaging features to clinically relevant tumour phenotypes.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Dongchan Kim, Bhavya Gupta, Geoffrey Yuet Mun Wong
Summary: The liver is the most common site of metastasis in colorectal cancer. Multimodal treatment, including liver resection, is potentially curative and prolongs survival for selected patients with colorectal liver metastases (CRLM). However, the treatment of CRLM remains challenging because recurrence is common, and prognosis varies widely between patients despite curative-intent treatment. Clinicopathological features and tissue-based molecular biomarkers, either alone or in combination, are insufficient for accurate prognostication. As most of the functional information in cells resides in the proteome, circulating proteomic biomarkers may be useful for rationalising the molecular complexities of CRLM and identifying potentially prognostic molecular subtypes. High-throughput proteomics has accelerated a range of applications including protein profiling of liquid biopsies for biomarker discovery. Moreover, these proteomic biomarkers may provide non-invasive prognostic information even before CRLM resection. This review evaluates recently discovered circulating proteomic biomarkers in CRLM. We also highlight some of the challenges and opportunities with translating these discoveries into clinical applications. (c) 2023 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2023)
Article
Oncology
Aradhya Nigam, Jason S. Hawksworth, Emily R. Winslow
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mignote Yilma, Neil Mehta
Summary: Liver transplantation (LT) remains the optimal treatment for hepatocellular carcinoma (HCC), but considerations must be given to organ availability and risk of recurrence. In the United States, Milan criteria have been used to maximize the benefit of LT compared to alternative treatments. Advances in local regional therapy (LRT) have allowed us to downstage patients to meet Milan criteria, and newer selection criteria incorporating biomarkers and imaging are being developed to further optimize LT for HCC patients.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anthony Bejjani, Richard S. Finn
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Ifrah Fatima, Neehar D. Parikh, Alisa Likhitsup
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria Chernyak
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Gloria Y. Chang, Adam C. Yopp
Summary: HCC is the third leading cause of cancer-related deaths worldwide and its prognosis is complex and diverse, requiring consideration of tumor burden, biology, liver function, and patient status in treatment decision-making.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mikin Patel, Anjana Pillai
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Zachary Whitham, David Hsiehchen
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mariana Chavez-Villa, Ismael Dominguez-Rosado
Summary: Over the past 40 years, multiple staging systems have been developed for hepatocellular carcinoma (HCC) to guide treatment and determine prognosis. However, the heterogeneity of HCC and advances in diagnostic and therapeutic tools have made staging algorithms and eligibility criteria more complex. Recent advances in neoadjuvant therapy, downstaging, and adjuvant therapy have challenged traditional paradigms but also raised new questions. Although there is no perfect or universal staging system yet, models will continue to be refined as evidence advances. Individualized decision making and multidisciplinary approaches will play key roles in the management of HCC.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
